ADVA
13.4.2021 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated interoperability between its next-generation FSP 3000 DCI open line system (OLS) and QSFP-DD 400ZR modules from Acacia Communications and Inphi Corporation. Conducted over a 120km amplified link, the tests show a clear path to commercial deployments of a complete solution with all the benefits of open, programmable networking. The trial featured 400Gbit/s WDM transport using low-power 400ZR pluggable QSFP-DD transceivers from Acacia and Inphi with ADVA’s FSP 3000 DCI OLS . It was carried out under real-world conditions with 400Gbit/s channels placed next to the test channels as well as a fully loaded spectrum. To validate three-way line-side interoperability, 400ZR was transmitted from Acacia to Inphi and vice versa. Test results showed that this multi-vendor ecosystem exceeds all OIF 400ZR Implementation Agreement performance metrics. Large-scale DCI network operators now have an easy and cost-effective route to a dynamic, future-proof and open environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005107/en/
“Today, we’re showing a direct route to open DCI networking using 400ZR. By proving the next-level interoperability of our platform with Acacia and Inphi’s optical interconnect technology, we’re empowering network operators to effortlessly harness the benefits of both 400ZR and open infrastructure. This will be key to reducing cost and complexity in the new breed of high-bandwidth DCI networks,” said Steve Penticost, VP, global business development, ADVA. “Others may talk about openness, but our track record with multi-vendor innovation speaks for itself. With thousands of our DCI OLS deployed, we’re already giving huge numbers of networks across the planet the freedom to select any components and leverage different innovation cycles.”
The ADVA FSP 3000 DCI OLS is the market’s most comprehensive OLS platform. Its open and modular design removes all restrictions of traditional closed systems and puts DCI network operators in complete control. With ADVA’s unrivalled experience of managing APIs in DCI architectures, the platform extends SDN to the transport layer. Designed to interoperate with all standards-based DWDM pluggable optics, the ADVA DCI OLS now features components specifically engineered to meet 400ZR DCI demands. The latest trials using a 120km single-mode fiber show that it exceeds 400ZR performance requirements under fully loaded conditions including 75GHz channel spacing, enabling an aggregate capacity of 26Tbit/s per fiber. ADVA’s DCI OLS and Acacia and Inphi’s QSFP-DD 400ZR modules offer operators a complete and validated solution built on best-of-breed components.
“Acacia has a long, proven history of pluggable silicon photonics innovation and has continually driven down the level of power consumption, size and cost of coherent interconnects,” said Tom Williams, VP, marketing, Acacia Communications. “400Gbit/s coherent pluggables enable network operators to support their growing bandwidth demands using power-efficient solutions that offer operational flexibility. By showcasing the interoperability of our high-performance coherent platform in a QSFP form factor with ADVA’s new DCI OLS, we’re giving DCI networks a clear path to a compact and cost-efficient optical layer assembled with best-in-class innovation.”
“With the introduction of COLORZ® 100G in 2016, Inphi’s silicon photonics-based QSFP transceivers along with ADVA’s line systems created a simpler and more cost-efficient way to connect data centers. Inphi’s COLORZ® II 400ZR QSFP-DD transceiver, with its low-power coherent DSP and silicon photonics engine, takes IP over DWDM to the next level. COLORZ® II 400ZR enables large cloud operators to connect metro data centers at a fraction of the cost of traditional coherent transport systems and allows switch and router companies to offer the same density for both coherent DWDM and client optics in the same chassis. Interoperable 400ZR solutions allow customers to deploy a validated ecosystem with our innovative low-power, high-performing pluggable solutions and ADVA’s next-generation DCI OLS,” said Josef Berger, AVP, optical interconnect, Inphi. “400ZR empowers DCI operators to select best-in-class components that reduce the total cost of ownership of their cloud networks.”
More information on the demo is available in these slides: https://adva.li/acacia-inphi-demo-slides .
Watch this video for further details on the new ADVA DCI OLS: https://youtu.be/8zI3E46oMBo .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
All trademarks used herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005107/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom